News
- The digital-only Program & Abstract book is now available for download here.
Program
SATURDAY, MAY 7, 2022
Click on the track name to expand the program.
8:30 - 8:45: Welcome address by BELNUC President
Green+Blue
9:00 - 10:30: The role of PET in dementia : current clinical use and novel targets for the near future
Green+Blue
| Moderators: Koen Van Laere and Thierry Vander Borght | |
| 09:00 - 09:40 | |
| Clinical PET in dementia : an update on FDG and amyloid Prof. Eric Salmon (BE) | |
| 09:40 - 10:10 | |
| Advances in tau imaging : ready for clinical use ? Prof. Alexander Drzezga (DE) | |
| 10:10 - 10:30 | |
| Synaptic density in dementia : a better marker than FDG ? Prof. Koen Van Laere (BE) | |
10:30 - 11:00: Coffee break
Hall 4
11:00 - 12:00: Proffered papers
Green+Blue
| Moderators: Géraldine Gebhart and Tim Van den Wyngaert | |
| 11:00 - 11:10 | [18F]AlF-NOTA-octreotide vs. [68Ga]Ga-DOTA-somatostatin analogue PET in neuroendocrine tumour patients: interim results of a prospective multicentre trial. Elin Pauwels (UZ Leuven, Leuven) | |
| 11:10 - 11:20 | Yttrium-90 radioembolization versus drug-eluting beads chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE trial. Bieke Lambert (UGent, Gent) | |
| 11:20 - 11:30 | Comparison between Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE and external beam radiation therapy. Wendy Delbart (Institut Jules Bordet, Anderlecht) | |
| 11:30 - 11:40 | 3p-C-NETA-TATE: A versatile somatostatin analogue for Al18F-labeled and therapeutic SSTR2 targeting radiopharmaceuticals. Stephen Ahenkorah (SCK CEN, Mol) | |
| 11:40 - 11:50 | Disturbing the redox balance as a new radiosensitizing strategy for Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Wendy Delbart (Institut Jules Bordet, Anderlecht) | |
| 11:50 - 12:00 | Bone SPECT/CT for assessing persistent or recurrent pain post spondylodesis: a retrospective study and pattern analysis. Bieke Lambert (AZ Maria Middelares, Gent) | |
12:00 - 13:00: Lunch break (Hall 4)
12:00 - 13:00: Poster viewing (Hall 4)
13:00 - 14:00: Reimbursement of radionuclide therapies in Belgium
Green+Blue
| Moderators: N/A and N/A | |
| 13:00 - 13:30 | |
| Update on BELNUC proposal for revision of nomenclature TBD () | |
| 13:30 - 14:00 | |
| Interactive panel discussion () | |
14:00 - 15:30: Upcoming technologies
Green+Blue
| Moderators: Cédric Reichel and Nadia Withofs | |
| 14:00 - 14:45 | |
| Is total body PET/CT here to stay? An investigation into clinical applications of a new imaging technique Prof. Stefaan Vandenberghe (BE) | |
| 14:45 - 15:30 | |
| What to expect from annular SPECT/CT. A clinical center's opinion. Dr. Matthieu Bailly (FR) | |
15:30 - 16:00: Coffee break
Hall 4
16:00 - 17:20: Young nuclearist challenge
Green+Blue
| Moderators: Félicie Sherer and Sander Jentjens | |
| 16:00 - 16:10 | The nerve-racking case of [18F]PSMA-1007 PET/CT in a patient with continuous low back pain. Anne-Leen Deleu (UZ Leuven, Leuven) | |
| 16:10 - 16:20 | Breaking the oculo-(para)neoplastic reflex on FDG-PET/CT: cerebellar hypermetabolism in a Hodgkin lymphoma leads to an unexpected diagnosis. Eef Vanerwegen (Imelda Hospital, Bonheiden) | |
| 16:20 - 16:30 | “Looks like the raccoon sign...” “Baboon?” “No, RACCOON!!!”. Lynn De Mey (UZ Brussel, Brussels) | |
| 16:30 - 16:40 | Just a little RE(nal)SPECT. Geraldine Lens (UZ Leuven, Leuven) | |
| 16:40 - 16:50 | Progestin-associated meningiomas: raising awareness about a causal oncological association. Amélie Castiaux (Institut Jules Bordet, Anderlecht) | |
| 16:50 - 17:00 | Idiopathic SIADH: 4 years of diagnostic wandering. Omar Mzaiti (CHU Liège, Liège) | |
| 17:00 - 17:10 | 18F-FDG PET/CT unveils a cyst with a twist. Pieter Claes (Ziekenhuis Oost-Limburg, Genk) | |
| 17:10 - 17:20 | Femoral osteonecrosis in the setting of myelodysplastic syndrome with blasts excess. Isaac Kargar Samani (CHU UCL Namur - Site Godinne, Yvoir) | |
17:30 - 18:30: Keynote lecture + BELNUC awards
Green+Blue
| Moderators: Sophie Bourgeois and Géraldine Gebhart | |
| 17:30 - 18:15 | |
| Keynote lecture: Cancer molecular imaging and immunotherapy Prof. Elisabeth de Vries (NL) | |
| 18:15 - 18:30 | |
| BELNUC award ceremony Koen + Géraldine () | |
8:30 - 8:45: Welcome address by BELNUC President
Green+Blue
9:00 - 10:30: The role of PET in dementia : current clinical use and novel targets for the near future
Green+Blue
| Moderators: Koen Van Laere and Thierry Vander Borght | |
| 09:00 - 09:40 | |
| Clinical PET in dementia : an update on FDG and amyloid Prof. Eric Salmon (BE) | |
| 09:40 - 10:10 | |
| Advances in tau imaging : ready for clinical use ? Prof. Alexander Drzezga (DE) | |
| 10:10 - 10:30 | |
| Synaptic density in dementia : a better marker than FDG ? Prof. Koen Van Laere (BE) | |
10:30 - 11:00: Coffee break
Hall 4
ROOM CHANGE: Join the pharmacy track in Orange room (2nd floor)
11:00 - 12:00: GMP, quality and regulations + proffered papers
Orange
| Moderators: Filip De Vos and Dominique Vanderghinste | |
| 11:00 - 11:25 | |
| Implementing the PIC/S guide in nuclear medicine: a practical guidance Filip De Vos (BE) and Caroline Vermeiren (BE) | |
| Selected abstracts: | |
| 11:25 - 11:36 | Development and evaluation of a trans-cyclooctene (TCO) probe for pretargeted PET imaging. Karuna Adhikari (University of Antwerp, Antwerp) | |
| 11:36 - 11:47 | Site-specific conjugation of fluorescent dyes and chelators on antibody fragments via maleimide-thiol chemistry. Simon Leekens (Laboratory of Radiopharmaceutical Research KU Leuven, Leuven) | |
| 11:47 - 12:00 | Development and in vitro evaluation of caspase-3-selective PET probes. Louis Lauwerys (University of Antwerp, Antwerp) | |
12:00 - 13:00: Lunch break (Hall 4)
13:00 - 14:00: Reimbursement of radionuclide therapies in Belgium
Green+Blue
| Moderators: N/A and N/A | |
| 13:00 - 13:30 | |
| Update on BELNUC proposal for revision of nomenclature TBD () | |
| 13:30 - 14:00 | |
| Interactive panel discussion () | |
14:00 - 15:30: F-18 and C-11 chemistry + proffered papers
Orange
| Moderators: Guy Bormans and Simon Lacroix | |
| 14:00 - 14:50 | |
| Prosthetic group-based 18F labelling of peptides and proteins Dr. Térence Tshibangu Tshikondu Tshiamalu (BE) | |
| Selected abstracts: | |
| 14:50 - 15:03 | Preclinical validation of [18F]-FB-(Anti Human PD-L1) Nanobody for PET imaging. Herlinde Dierick (Vrije Universiteit Brussel (VUB), Brussels) | |
| 15:03 - 15:16 | Development and preclinical evaluation of [11C]HSP990 as an Hsp90 PET brain probe and potential biomarker for diagnosis and follow up of CNS disease progression. Romy Cools (Laboratory for Radiopharmaceutical Research KU Leuven, Leuven) | |
| 15:16 - 15:30 | Second generation Al18F-labeled D-amino acid based peptide for CXCR4 targeted molecular imaging. Spahn Muriel (KU Leuven, Leuven) | |
15:30 - 16:00: Coffee break (Hall 4)
16:00 - 17:20: Theranostics + proffered papers
Orange
| Moderators: Vicky Caveliers and Zena Wimana | |
| 16:00 - 16:30 | |
| Theranostic radiopharmaceuticals: where are we now? Prof. Rudolf Werner (DE) | |
| 16:30 - 17:00 | |
| Recent advances in chelators for alpha emitters Dr. Sophie Poty (FR) | |
| Selected abstracts: | |
| 17:00 - 17:10 | RANKL immunoPET using 64Cu radiolabeled antibody Fab fragments to improve imaging characteristics. Jonatan Dewulf (University of Antwerp, Antwerp) | |
| 17:10 - 17:20 | Using the site-specific radiolabeling of a PD-L1 nanobody via maleimide–cysteine chemistry to develop a PET-tracer as screening tool for personalized oncology treatment. Dora Mugoli Chigoho (Vrije Universiteit Brussel, Brussels) | |
ROOM CHANGE: Join the plenary session in Green+Blue room (1st floor)
17:30 - 18:30: Keynote lecture + BELNUC awards
Green+Blue
| Moderators: Sophie Bourgeois | |
| 17:30 - 18:15 | |
| Keynote lecture: Cancer molecular imaging and immunotherapy Prof. Elisabeth de Vries (NL) | |
| 18:15 - 18:30 | |
| BELNUC award ceremony | |
8:30 - 8:45: Welcome address by BELNUC President
Green+Blue
9:00 - 10:30: The role of PET in dementia : current clinical use and novel targets for the near future
Green+Blue
| Moderators: Koen Van Laere and Thierry Vander Borght | |
| 09:00 - 09:40 | |
| Clinical PET in dementia : an update on FDG and amyloid Prof. Eric Salmon (BE) | |
| 09:40 - 10:10 | |
| Advances in tau imaging : ready for clinical use ? Prof. Alexander Drzezga (DE) | |
| 10:10 - 10:30 | |
| Synaptic density in dementia : a better marker than FDG ? Prof. Koen Van Laere (BE) | |
10:30 - 11:00: Coffee break
Hall 4
ROOM CHANGE: Join the physics track in Yellow room (2nd floor)
11:00 - 12:00: AI: from hype to medical physics?
Yellow
| Moderators: Stefaan Vandenberghe | |
| 11:00 - 11:30 | |
| AI in medical imaging Prof. Erik Ranschaert (BE) | |
| 11:30 - 12:00 | |
| AI in nuclear medicine Prof. Dimitris Visvikis (FR) | |
12:00 - 13:00: Lunch break (Hall 4)
12:00 - 13:00: Poster viewing (Hall 4)
13:00 - 14:00: Reimbursement of radionuclide therapies in Belgium
Green+Blue
| Moderators: N/A and N/A | |
| 13:00 - 13:30 | |
| Update on BELNUC proposal for revision of nomenclature TBD () | |
| 13:30 - 14:00 | |
| Interactive panel discussion () | |
14:00 - 15:30: Applications of AI in nuclear medicine
Yellow
| Moderators: Michel Koole and Stijn De Schepper | |
| 14:00 - 14:30 | |
| Starting an AI project Zelda Paquier (BE) | |
| 14:30 - 15:00 | |
| Image reconstruction Dr. Georg Schramm (BE) | |
| 15:00 - 15:30 | |
| Radiomics Dr. Fanny Orlhac (FR) | |
15:30 - 16:00: Coffee break
Hall 4
16:00 - 17:20: Isotopes of the future + proffered papers
Yellow
| Moderators: Claire Bernard and Bruno Vanderlinden | |
| 16:30 - 16:40 | Dosimetric model for patients with renal failure undergoing dialysis during I-131 therapy for thyroid cancer. Victor Nuttens (OLV Aalst, Aalst) | |
| 16:40 - 16:50 | Development of an anthropomorphic phantom for mandibular condyle imaging. Stijn De Schepper (UZA, Antwerpen) | |
| 16:50 - 17:00 | Feasibility of lesion dosimetry assuming constant pharmacokinetics over cycles in patients treated with 177Lu-DOTATATE. Rachele Danieli (Institut Jules Bordet, Anderlecht) | |
| 17:00 - 17:10 | Radiation dose optimization of CT acquisitions in SPECT/CT examinations. Lauren Podevyn (UGent, Ghent) | |
| 17:10 - 17:20 | StarGuide Tc-99m imaging reconstruction parameters optimization. Jirair Karabet (Institut Jules Bordet, Anderlecht) | |
ROOM CHANGE: Join the plenary session in Green+Blue room (1st floor)
17:30 - 18:30: Keynote lecture + BELNUC awards
Green+Blue
| Moderators: Sophie Bourgeois | |
| 17:30 - 18:15 | |
| Keynote lecture: Cancer molecular imaging and immunotherapy Prof. Elisabeth de Vries (NL) | |
| 18:15 - 18:30 | |
| BELNUC award ceremony | |
8:30 - 8:45: Welcome address by BELNUC President
Red+Purple
ROOM CHANGE: Join the technologist track in Red+Purple room (2nd floor)
9:00 - 10:30: Clinical update
Red+Purple
| Moderators: Sara Vieira and Kim Van Hullebusch | |
| 09:00 - 09:45 | |
| Cardiac PET: patient preparation, acquisition, and clinical applications Prof. Olivier Gheysens (BE) | |
| 09:45 - 10:30 | |
| Nuclear medicine in endocrinology: an update Dr. Duran Derijckere (BE) | |
10:30 - 11:00: Coffee break
Hall 4
11:00 - 12:00: Clinical management
Red+Purple
| Moderators: Christelle Terwinghe and Geraldine Vandermeiren | |
| 11:00 - 11:30 | |
| Paediatric Patient care - Technologist practice improvement Mrs. Andrea Santos (PT) | |
| 11:30 - 12:00 | |
| Patient communication Mrs. Hanne Kindermans (BE) | |
12:00 - 13:00: Lunch break (Hall 4)
13:00 - 14:00: Reimbursement of radionuclide therapies in Belgium
Green+Blue
| Moderators: N/A and N/A | |
| 13:00 - 13:30 | |
| Update on BELNUC proposal for revision of nomenclature TBD () | |
| 13:30 - 14:00 | |
| Interactive panel discussion () | |
14:00 - 15:30: Radionuclide therapy
Red+Purple
| Moderators: Bram Van Landeghem and Wouter Daenen | |
| 14:00 - 14:45 | |
| Calibration of non-imaging instrumentation Prof. Kristof Baete (BE) | |
| 14:45 - 15:30 | |
| Apha emitters: current and future applications Dr. Maarten Ooms (BE) | |
15:30 - 16:00: Coffee break
Hall 4
16:00 - 17:20: FANC session + Proffered papers
Red+Purple
| Moderators: Jean-Paul Thys and Filip Lavent | |
| 16:00 - 16:30 | |
| Radionuclide therapy waste management Mrs. Jolien Berlamont (BE) | |
| Selected abstracts: | |
| 16:30 - 16:42 | Logistical analysis of the individual "whole body" dosimetry of personnel professionally exposed to ionizing radiation in Belgium, over the last 10 years. Ana Mafalda Pereira Gomes (Vinçotte S.A, Vilvoorde) | |
| 16:42 - 16:54 | Design of an integrated Radiopharmaceutical Supply Chain (SC) to enhance its overall Supply Chain Performance Methodology. Rabarijaona Haingo (Université Libre de Bruxelles, Brussels) | |
| 16:54 - 17:06 | Can a third party software vendor (MIMVista) match the image quality of native software vendor?. Bram Van Landeghem (AZ Jan Palfijn Gent, Ghent) | |
| 17:06 - 17:20 | Implementing Lutetium-177 PSMA ligand therapy: practical aspects concerning radioprotection and dosimetry. Nico Dhondt (AZ Maria Middelares, Ghent) | |
ROOM CHANGE: Join the plenary session in Green+Blue room (1st floor)
17:30 - 18:30: Keynote lecture + BELNUC awards
Green+Blue
| Moderators: Sophie Bourgeois | |
| 17:30 - 18:15 | |
| Keynote lecture: Cancer molecular imaging and immunotherapy Prof. Elisabeth de Vries (NL) | |
| 18:15 - 18:30 | |
| BELNUC award ceremony | |
SUNDAY, MAY 8, 2022
9:00 - 10:00: Clinical state of PET/MR
Green+Blue
| Moderators: Koen Van Laere and Vanessa Schelfhout | |
| 09:00 - 09:30 | |
| PET/MRI in brain imaging Prof. Ian Law (DK) | |
| 09:30 - 10:00 | |
| PET/MRI in oncology Prof. Irene Burger (CH) | |
10:00 - 10:30: Coffee break
Hall 4
10:30 - 12:15: Are we ready for artificial intelligence?
Green+Blue
| Moderators: Patrick Flamen and Anne Delcourt | |
| 10:30 - 10:55 | |
| The technical and methodological aspects of AI Prof. Irene Buvat (FR) | |
| 10:55 - 11:20 | |
| Medical applications of AI with focus on (nuclear) imaging Prof. Henry Woodruff (NL) | |
| 11:20 - 12:00 | |
| The ethical and legal aspects of AI in healthcare Prof. Tom Goffin (BE) | |
Abstracts
Click on the track name to view the abstract titles.
The full-text of the abstracts is available in the digital Program & Abstract book.
Oral presentations
OP-MED1
[18F]AlF-NOTA-octreotide vs. [68Ga]Ga-DOTA-somatostatin analogue PET in neuroendocrine tumour patients: interim results of a prospective multicentre trial
Elin Pauwels1, Frederik Cleeren2, Terence Tshibangu3, Michel Koole3, Kim Serdons2, Lennert Boeckxstaens1, Jeroen Dekervel2, Timon Vandamme2, Willem Lybaert4, Bliede Van den Broeck5, Paul Clement6, Karen Geboes6, Eric van Cutsem7, Sigrid Stroobants8, Chris Verslype9, Guy Bormans4, Christophe M. Deroose10;
1Nuclear Medicine and Molecular Imaging, Leuven, Belgium, 2Nuclear Medicine, Leuven, Belgium, 3Radiopharmaceutical Research, Leuven, Belgium, 4Digestive Oncology, Leuven, Belgium, 5Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Antwerp, Belgium, 6Oncology, Belgium, 7Nuclear Medicine, Ghent, Belgium, 8General Medical Oncology, Leuven, Belgium, 9Digestive Oncology, Ghent, Belgium, 10Nuclear Medicine, Wilrijk, Belgium.
OP-MED2
Yttrium-90 radioembolization versus drug-eluting beads chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE trial.
Bieke Lambert1, Elisabeth Dhondt2, Laurens Hermie2, Lynn Huyck2, Xavier Verhelst2, Hans Van Vlierberghe2, Peter Vanlangenhove2, Anja Geerts2, Aude Vanlander2, Frederik Berrevoet2, Roberto Troisi3, Luc Defreyne2;
1UGent, Gent, Belgium, 2UZ Gent, 3UGent.
OP-MED3
Comparison between Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE and external beam radiation therapy
Wendy Delbart1, Gwennaëlle Marin1, Jirair Karabet1, Ghanem Ghanem1, Patrick Flamen1, Zéna Wimana1;
1Institut Jules Bordet.
OP-MED4
3p-C-NETA-TATE: A versatile somatostatin analogue for Al18F-labeled and therapeutic SSTR2 targeting radiopharmaceuticals
Stephen Ahenkorah1, Erika Murce Silva2, Christopher Cawthorne3, Yann Seimbille4, Thomas Cardinaels3, Christophe M. Deroose4, Guy Bormans1, Maarten Ooms5, Frederik Cleeren4;
1SCK CEN, Mol, Belgium, 2University of Leuven, Leuven, Belgium, 3Erasmus MC, Rotterdam, Netherlands, 4Katholieke Universiteit Leuven, Leuven, Belgium, 5UZ Leuven Gasthuisberg Campus, Leuven, Belgium.
OP-MED5
Disturbing the redox balance as a new radiosensitizing strategy for Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
Wendy Delbart1, Gwennaëlle Marin1, Basile Stamatopoulos1, Ghanem Ghanem1, Patrick Flamen1, Zéna Wimana1;
1Institut Jules Bordet.
OP-MED6
Bone SPECT/CT for assessing persistent or recurrent pain post spondylodesis: a retropective study and pattern analysis
Bieke Lambert1, Bieke Van Den Bossche2, Jeroen Mertens2, Dieter Berwouts2, Joris Bleyen2, André Harth3, Tom Matton2, Tim Van den Wyngaert4;
1AZ Maria Middelares; AZ Jan Palfijn; UGent, 2AZ Maria Middelares, Gent, 3AZ Jan Palfijn Gent, 4UZA.
Poster presentations
PP-MED1
Does the semiquantitative assessment of cardiac upake of 99m-Tc-HDP predicts survival in patients with suspected transthyretin cardiac amyloidosis?
Pieter De Bondt1, Victor Nuttens2, Sim Vermeulen2, Dirk Ooms1, Olivier De Winter2, Marc Vanderheyden1, Nicole Dorny2;
1ASZ Hopital, Aalst, Belgium, 2Onze Lieve Vrouwziekenhuis, Aalst, Belgium.
PP-MED2
Are the values from different myocardial perfusion quantification programs interchangeable?
Pieter De Bondt1, Victor Nuttens2, Sim Vermeulen1, Dirk Ooms2, Olivier De Winter1;
1Onze Lieve Vrouwziekenhuis, Aalst, Belgium, 2ASZ Hopital, Aalst, Belgium.
PP-MED3
The investigations of the deep lymphatic system of the lower limbs: spect-ct is mandatory!
Pierre Bourgeois1, Gary Callebaut1;
1HIS-IZZ Hospitals, Brussels, Belgium.
PP-MED4
The popliteal lymph nodes and the investigations of the superficial lymphatic system of the lower limbs: spect-ct is recommended!
Pierre Bourgeois1, Gary Callebaut1;
1HIS-IZZ Hospitals, Brussels, Belgium.
PP-MED5
“Natural History” of Dermal BackFlows? Insights from lymphoscintigraphic investigations and practical recommendations
Pierre Bourgeois1, Gary Callebaut1;
1HIS-IZZ Hospitals, Brussels, Belgium.
PP-MED6
“Retex” from lymphoscintigraphic investigations in the management of lower limb edemas in Belgium
Pierre Bourgeois1;
1HIS-IZZ Hospitals, Brussels, Belgium.
Oral presentations
OP-YNC1
The nerve-racking case of [18F]PSMA-1007 PET/CT in a patient with continuous low back pain
Anne-Leen Deleu1, Lodewijk Van Wynsberge2, Wouter Everaerts1, Koenraad Van Laere1, Gert De Meerleer1, Karolien Goffin1, Niloefar Ahmadi Bidakhvidi1;
1University Hospitals Leuven, Leuven, Belgium, 2Tienen Regional Hospital, Tienen, Belgium.
OP-YNC2
Breaking the oculo-(para)neoplastic reflex on FDG-PET/CT: cerebellar hypermetabolism in a Hodgkin lymphoma leads to an unexpected diagnosis.
Eef Vanerwegen1, Niloefar Ahmadi Bidakhvidi2, Vibeke KJ Vergote2, Ann Janssens3, Koen Van Laere2, Christophe Deroose2;
1Imelda Hospital, Bonheiden, Belgium, 2University Hospitals Leuven, Leuven, Belgium, 3KU Leuven, Leuven, Belgium.
OP-YNC3
“Looks like the raccoon sign…” “Baboon?” “No, RACCOON!!!”
Lynn De Mey1, Kristoff Muylle2, Sophie Bourgeois1, Jeroen de Filette1, Odrade Gondry1, Amelientje Bracke1, Lode Goethals1, Hendrik Everaert1, Tony Lahoutte1;
1UZ Brussel, 2AZ Delta.
OP-YNC4
Just a little RE(nal)SPECT
Geraldine Lens1, Raf Verscuren1, Koenraad Van Laere1, Frank Van der Aa1, Karolien Goffin1;
1UZ Leuven, Leuven, Belgium.
OP-YNC5
Progestin-associated meningiomas: raising awareness about a causal oncological association.
Amélie Castiaux1, Patrick Flamen1, Ioannis Karfis1;
1Institut Jules Bordet, Bruxelles, Belgium.
OP-YNC6
Idiopathic SIADH: 4 years of diagnostic wandering
Omar Mzaiti1;
1Chu De Liège, Luik, Belgium.
OP-YNC7
18F-FDG PET/CT unveils a cyst with a twist
Pieter Claes1, Peter Van Eyken2, Yannic Raskin1, Eric De Jonge1, Charlotte Bevernage1, Koen Van Laere1, Liesbet Mesotten3;
1Ziekenhuis Oost-Limburg, Genk, Belgium, 2University Hospitals Leuven, Leuven, Belgium, 3KU Leuven, Leuven, Belgium.
OP-YNC8
Femoral osteonecrosis in the setting of myelodysplastic syndrome with blasts excess
Isaac Kargar Samani1, Yassin Akachar1, Anne Sonet1, Elodie Collinge1, Carlos Graux1, Thierry Vander Borght1, Bruno Krug1;
1CHU UCL Namur – Site Godinne, Yvoir, Belgium.
Poster presentations
PP-YNC1
A mysterious case of a persistent hypermetabolism in the bone marrow
Juanito Gebruers1, Sherida Woei-A-Jin1, Daniel Blockmans1, Koen Van Laere1, Christophe Deroose2;
1University Hospitals Leuven, Leuven, Belgium, 2KU Leuven.
PP-YNC2
Inflammation PET: don’t forget the head.
Lennert Boeckxstaens1, Daniël Blockmans2, Koenraad Van Laere1;
1University Hospitals Leuven, Leuven, Belgium, 2University Hospital Leuven , Leuven, Belgium.
PP-YNC3
Bilateral hot caudate nuclei, what diagnosis to be raised?
Silvano Marchiori1;
1CHU of Liege, Liège, Belgium.
PP-YNC4
Progressively worsening back pain in a 16 year old patient
Odrade Gondry1, Lode Goethals1, Sophie Bourgeois1, Lynn De Mey1, David Van Schaik1, Amelientje Bracke1, Hendrik Everaert1, Tony Lahoutte1, Kristoff Muylle2;
1Universitair Ziekenhuis Brussel, Jette, Belgium, 2AZ Delta, Roeselare, Belgium.
PP-YNC5
When phagocytosis goes wrong
Marine Stoffels1;
1Hospital Center Universitaire De Liège, Luik, Belgium.
PP-YNC6
18FDG PET/CT of Takayasu arteritis in a 13-year-old girl.
Eman Sirfouq1, Hendrik Everaert2, Sophie Bourgeois2, Lode Goethals1, Tony Lahoutte2;
1UZ Brussel, Belgium, 2UZ Brussel, Jette, Belgium.
PP-YNC7
Concomitant finding of a large vessel vasculitis and a colorectal neoplasia on FDG PET/CT
Isaac Kargar Samani1, Anne-Sophie Pirson1, Bruno Krug1, Thierry Vander Borght1;
1CHU UCL Namur – Site Godinne, Yvoir, Belgium.
PP-YNC8
Rare transformation of hairy cell leukemia to high-grade lymphoma: a case report.
Paulien Moyaert1, Hendrik Everaert2, Lode Goethals3, Udunna Anazodo3, Eric Achten3, Sophie Bourgeois4;
1UZ Gent, Gent, Belgium, 2Western University, London, Ontario, Canada, 3UZ Brussel, Brussels, Belgium, 4McGill University.
PP-YNC9
Infection or inflammation? That’s the question. A fracture-related infection detected by FDG PET/CT.
Nick van Rijsewijk1, Frank IJpma1, Marjan Wouthuyzen-Bakker1, Andor Glaudemans1;
1University Medical Center Groningen, Groningen, Netherlands.
Oral presentations
OP-PHARM1
Preclinical validation of [18F]-FB-(Anti Human PD-L1) Nanobody for PET imaging
Herlinde Dierick1, Karine Breckpot2, Devoogdt Nick3, Marleen Keyaerts1, Caveliers Vicky1, Tony Lahoutte2, Jessica Bridoux1;
1Vrije Universiteit Brussel (VUB), Brussel, Belgium, 2Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium, 3Vrije Universiteit Brussel, Jette, Belgium.
OP-PHARM2
Using the site-specific radiolabeling of a PD-L1 nanobody via maleimide–cysteine chemistry to develop a PET-tracer as screening tool for personalized oncology treatment
Dora Mugoli Chigoho1, Jessica Bridoux1, Quentin Lecocq1, Robin Maximilian Awad1, Karine Breckpot1, Nick Devoogdt1, Marleen Keyaerts1, Vicky Caveliers2, Catarina Xavier1;
1Vrije Universiteit Brussel, Brussels, Belgium, 2UZ Brussel, Brussels, Belgium.
OP-PHARM3
RANKL immunoPET using 64Cu radiolabeled antibody Fab fragments to improve imaging characteristics.
Jonatan Dewulf1, Tim Van den Wyngaert1, Filipe Elvas1;
1University of Antwerp, Antwerpen, Belgium.
OP-PHARM4
Development and preclinical evaluation of [11C]HSP990 as an Hsp90 PET brain probe and potential biomarker for diagnosis and follow up of CNS disease progression
Romy Cools1, Koen Vermeulen2, Christopher Cawthorne3, Guy Bormans1;
1Laboratory for Radiopharmaceutical Research KU Leuven, Leuven, Belgium, 2Radiobiology Unit & NURA Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium, 3Nuclear Medicine & Molecular Imaging & MoSAIC KU Leuven, Leuven, Belgium.
OP-PHARM5
Development and evaluation of a trans-cyclooctene (TCO) probe for pretargeted PET imaging
Karuna Adhikari1, Filipe Elvas2, Sigrid Stroobants2, Pieter Van der Veken1, Koen Augustyns1;
1University of Antwerp, Antwerpen, Belgium, 2University of Antwerp,.
OP-PHARM6
Site-specific conjugation of fluorescent dyes and chelators on antibody fragments via maleimide-thiol chemistry.
Simon Leekens1, Guy Bormans1, Frederik Cleeren1;
1Laboratory of Radiopharmaceutical Research, KU Leuven, Leuven, Belgium.
OP-PHARM7
Development and in vitro evaluation of caspase-3-selective PET probes
Louis Lauwerys1, Angelo Solania2, Lucas Beroske1, Stef De Lombaerde3, Pieter Van der Veken1, Dennis Wolan2, Filipe Elvas1;
1University of Antwerp, Antwerp, Belgium, 2The Scripps Research Institute, La Jolla, United States of America, 3University Hospital Antwerp (UZA), Antwerp, Belgium.
OP-PHARM8
Second generation Al18F-labeled D-amino acid based peptide for CXCR4 targeted molecular imaging
Spahn Muriel1, Kaat Luyten1, Frederik Cleeren1, Tom Van Loy1, Christopher Cawthorne1, Christophe Deroose1, Dominique Schols1, Guy Bormans1;
1Leuven, Leuven, Belgium.
Oral presentations
OP-PHYS1
Dosimetric model for patients with renal failure undergoing dialysis during I-131 therapy for thyroid cancer
Victor Nuttens1, Rogier Caluwé1, Paul Van Combrugge1, Olivier De Winter1;
1OLV Aalst.
OP-PHYS2
Development of an anthropomorphic phantom for mandibular condyle imaging
Stijn De Schepper1, Olivier Lenssen2, Gopinath Gnanasegaran3, John C Dickson4, Tim Van den Wyngaert5;
1University of Antwerp, Wilrijk, Belgium, 2Antwerp University Hospital, Edegem, Belgium, 3ZNA Middelheim, Antwerp, Belgium, 4Royal Free Hospital, London, United Kingdom, 5University College of London Hospitals, London, United Kingdom.
OP-PHYS3
Feasibility of lesion dosimetry assuming constant pharmacokinetics over cycles in patients treated with 177Lu-DOTATATE
Rachele Danieli1, Gwennaëlle Marin1, Magdalena Mileva1, Bruno Vanderlinden1, Ioannis Karfis1, Patrick Flamen1, Hugo Levillain1;
1Institut Jules Bordet, Anderlecht, Belgium.
OP-PHYS4
Radiation dose optimization of CT acquisitions in SPECT/CT examinations
Lauren Podevyn1, Jitske Hostens1, Gwenny Verfaillie1, Klaus Bacher1, Yves D’Asseler1;
1Ghent University, Ghent , Belgium.
OP-PHYS5
StarGuide Tc-99m imaging reconstruction parameters optimization
Jirair Karabet1, Gwennaelle Marin1, Clementine Marin1, Bruno Vanderlinden1;
1Jules Bordet Institute, Brussesls, Belgium.
Poster presentation
PP-PHYS1
CT dose optimization in PET/CT examinations
Jitske Hostens1, Lauren Podevyn1, Gwenny Verfaillie1, Klaus Bacher1, Yves D’Asseler1;
1Ghent University, Gent, Belgium.
Oral presentations
OP-TECH1
Logistical analysis of the individual “whole body” dosimetry of personnel professionally exposed to ionizing radiation in Belgium, over the last 10 years.
Ana Mafalda Pereira Gomes1;
1Vinçotte S.A, Vilvoorde, Belgium.
OP-TECH2
Design of an integrated Radiopharmaceutical Supply Chain (SC) to enhance its overall Supply Chain Performance Methodology
Haingo Rabarijaona1, Alassane Ndiaye2;
1Université Libre de Bruxelles, Brussels, 2Université Libre de Bruxelles, Brussels, Belgium.
OP-TECH3
Can a third party software vendor (MIMVista) match the image quality of native software vendor?
Bram Van Landeghem1, Tim Van den Wyngaert2, Jeroen Mertens3, Bieke Van Den Bossche1, Dieter Berwouts1, Bieke Lambert3;
1AZ Jan Palfijn Gent, Gent, Belgium, 2Universitair Ziekenhuis Antwerpen (UZA), Edegem, Belgium, 3AZ Maria Middelares Gent, Gent, Belgium.
OP-TECH4
Implementing Lutetium-177 PSMA ligand therapy: practical aspects concerning radioprotection and dosimetry
Nico Dhondt1, Luna Belmans2, Bieke Van Den Bossche1, Alex Maes3, Yves D’Asseler4, Dieter Berwouts1, Jeroen Mertens1, Bieke Lambert5;
1AZ Maria Middelares, Gent, 2Atheneum Gentbrugge, 3AZ Groeninge, Kortrijk, 4UGent, 5AZ Maria Middelares; AZ Jan Palfijn; UGent, Gent, Belgium.